Abstract
Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have